GRM2 and schizophrenia: Testing of selective mGlu2/3 receptor agonists in animal studies involving N-methyl-d-aspartate (NMDA) receptor antagonists like phencyclidine (PCP) provided early evidence that mGlu2/3 receptors may represent a novel target for schizophrenia treatment.